• Recruiting

NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM

Updated: Sep 16

NCT04634435: Phase 1/2: Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients

Newly diagnosed Multiple Myeloma

NDMM

BHV-1100 (KP1237)

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients


This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).


Sponsor

Biohaven Pharmaceuticals, Inc


Collaborator

Dana-Farber Cancer Institute


Locations

United States, Massachusetts

Dana Farber Cancer Institute

 

ClinicalTrials.gov Identifier: NCT04634435


Official Title: Phase 1 Study of Autologous Memory-like NK Cell Immunotherapy in Combination With KP1237 and Low Dose IL-2 as Early Post Autologous Transplant Consolidation in Minimal Residual Disease Positive, Newly Diagnosed Multiple Myeloma Patients


First Posted : November 18, 2020


Click here to see details on ClinicalTrials.gov

 

Combination Product: CIML NK Cells plus KP1237 and low dose IL-2

 

KP1237

CD38-targeting Antibody Recruiting Molecule KP1237 (Code C176834)

ARM KP1237

CD38-ARM KP1237

CD38-targeting Antibody Recruiting Molecule KP1237

CD38-targeting Antibody Redirecting Molecule KP1237

CD38-targeting ARM KP1237

KP 1237

KP-1237

KP1237

 

BIOHAVEN ENROLLS PHASE 1A/1B CLINICAL TRIAL OF BHV-1100, LEAD ASSET FROM ITS ARM™ (ANTIBODY RECRUITING MOLECULE) PLATFORM, IN COMBINATION WITH NK CELL THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA


NEW HAVEN, Conn., Oct. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced the enrollment of the first patient in a Phase 1a/1b trial in Multiple Myeloma using the ARM, BHV-1100, in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immunoglobulin (Ig) to target and kill multiple myeloma cells expressing the cell surface protein CD38.


Click here for details

 

Location

United States, Massachusetts



Posts Archive